New Harbor Capital has completed a majority equity investment in LGM Pharma, a company involved in distribution of cGMP active pharmaceutical ingredients (“API”) and other value-added services supporting leading pharmaceutical companies. 

“New Harbor’s strong track record of successfully executing growth strategies, as well as their experience with the healthcare industry and pharmaceutical services, will elevate our business to the next level while upholding the high quality, innovation and reliable service our customers expect,” said Gideon Schurder, commercial director at LGM Pharma.
 

“We welcome LGM to our growing healthcare portfolio,” said Jocelyn Stanley, principal at New Harbor Capital. “We are excited to partner with LGM’s co-founders Mendy and Gideon Schurder to support efforts to strategically grow the business.”